Результати пошуку - Véronique Dièras

Уточнити результати
  1. 1
    The taxanes: toxicity and quality of life considerations in advanced ovarian cancer

    The taxanes: toxicity and quality of life considerations in advanced ovarian cancer за авторством Jean Paul Guastalla, Véronique Dièras

    Опубліковано 2003
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Expert perspectives on biosimilar monoclonal antibodies in breast cancer

    Expert perspectives on biosimilar monoclonal antibodies in breast cancer за авторством Javier Cortés, Giuseppe Curigliano, Véronique Dièras

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  3. 3
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer

    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer за авторством Fanny Le Du, Véronique Dièras, Giuseppe Curigliano

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients

    First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients за авторством D.W. Miles, Véronique Dièras, Javier Cortés, Anja Duenne, Jingbo Yi, Joyce O’Shaughnessy

    Опубліковано 2013
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  5. 5
    Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen

    Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen за авторством Karim Fizazi, Bernard Asselain, Anne Vincent‐Salomon, Michel Jouve, Véronique Dièras, Thao Palangié, Philippe Beuzeboc, Thierry Dorval, P Pouillart

    Опубліковано 1996
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study

    Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study за авторством Véronique Dièras, Alain Lortholary, Valérie Laurence, R. Delva, V. Girre, Alain Livartowski, Sylvie Assadourian, Dorothée Sémiond, Jean‐Yves Pierga

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

    Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer за авторством Paul Cottu, Jamil Asselah, Marick Laé, J-Y Pierga, Véronique Dièras, L. Mignot, Brigitte Sigal‐Zafrani, Anne Vincent‐Salomon

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Carta
    Додати у Вибране
    Збережено в:
  8. 8
    New approaches for improving outcomes in breast cancer in Europe

    New approaches for improving outcomes in breast cancer in Europe за авторством Angelo Di Leo, Giuseppe Curigliano, Véronique Dièras, Luca Malorni, Christos Sotiriou, Charles Swanton, Alastair M. Thompson, Andrew Tutt, Martine Piccart

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  9. 9
    Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

    Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer за авторством Guy Jérusalem, Angelica Fasolo, Véronique Dièras, Fátima Cardoso, Jonas Bergh, Luc Vittori, Yufen Zhang, Cristian Massacesi, Tarek Sahmoud, Luca Gianni

    Опубліковано 2010
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

    Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy за авторством Ahmad Awada, Luc Dirix, Luís Manso, Binghe Xu, T Luu, Véronique Dièras, Dawn L. Hershman, V. Agrapart, Revathi Ananthakrishnan, Elżbieta Starosławska

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

    Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer за авторством Valentina Guarneri, David Miles, Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Ian Smith, Christoph Thomssen, Laura Biganzoli, Tanya Taran, Pierfranco Conté

    Опубліковано 2010
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

    Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exp... за авторством Ian E. Krop, Nancy U. Lin, Kimberly Blackwell, Ellie Guardino, Jens Huober, Mengdi Lu, David Miles, Meghna Samant, Manfred Welslau, Véronique Dièras

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis

    Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis за авторством Véronique Dièras, Nadia Harbeck, G. Thomas Budd, Joel K. Greenson, Alice E. Guardino, Meghna Samant, Nataliya Chernyukhin, Melanie C. Smitt, Ian E. Krop

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

    Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience за авторством L. Staudacher, P. Cottu, Véronique Dièras, Anne Vincent‐Salomon, M.N. Guilhaume, Lu Wang, Thierry Dorval, Philippe Beuzeboc, L. Mignot, Jean‐Yves Pierga

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    Survival of breast cancer patients with meningeal carcinomatosis

    Survival of breast cancer patients with meningeal carcinomatosis за авторством H. Gauthier, M.N. Guilhaume, François‐Clément Bidard, Jean‐Yves Pierga, V. Girre, Paul Cottu, Valérie Laurence, Alain Livartowski, L. Mignot, Véronique Dièras

    Опубліковано 2010
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age

    Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age за авторством Jean‐Yves Pierga, V. Girre, Valérie Laurence, Bernard Asselain, Véronique Dièras, M Jouve, Philippe Beuzeboc, Alain Fourquet, Claude Nos, Brigitte Sigal‐Zafrani, P Pouillart

    Опубліковано 2004
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC

    A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC за авторством P. Fumoleau, B Chevallier, Pierre Kerbrat, Yvan Krakowski, J. L. Misset, C. Maugard-Louboutin, Véronique Dièras, N. Azli, Nathalie Bougon, A. Riva, Henri Roché

    Опубліковано 1996
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

    High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic... за авторством Jean‐Yves Pierga, David Hajage, Thomas Bachelot, Suzette Delaloge, Étienne Brain, Mario Campone, Véronique Dièras, Emilie Rolland, L. Mignot, Claire Mathiot, François‐Clément Bidard

    Опубліковано 2011
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells

    Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells за авторством François‐Clément Bidard, Anne Vincent‐Salomon, Brigitte Sigal‐Zafrani, Véronique Dièras, Claire Mathiot, L. Mignot, Jean Paul Thiery, Xavier Sastre‐Garau, Jean‐Yves Pierga

    Опубліковано 2008
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC

    A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC за авторством Véronique Dièras, B Chevallier, Pierre Kerbrat, I. Krakowski, Henri Roché, JL Misset, M-A. Lentz, N. Azli, M Murawsky, A. Riva, P Pouillart, P. Fumoleau

    Опубліковано 1996
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: